Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Cenicriviroc mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Cenicriviroc mesylate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Paclitaxel Cationic Liposome Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Paclitaxel Cationic Liposome: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tenofovir Disoproxil Orotate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Tenofovir Disoproxil Orotate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Alveltamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Alveltamig: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Vanzacaftor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Vanzacaftor: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Cenopodlin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Cenopodlin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Noiiglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Noiiglutide: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Chiauranib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Chiauranib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Debio 4226 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Debio 4226: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Riminkefon Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Riminkefon: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bemnifosbuvir/Ruzasvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Bemnifosbuvir/Ruzasvir: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Pembrolizumab/Quavonlimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Pembrolizumab/Quavonlimab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.